{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"31.9","value":"6.7"},{"comment":"NA indicates that upper and lower limits of confidence interval (CI) were not estimable as there were no patients with CR or PR in that disease cohort.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG002","lowerLimit":"3.2","upperLimit":"37.9","value":"15.0"},{"groupId":"OG003","lowerLimit":"1.7","upperLimit":"40.5","value":"13.3"},{"groupId":"OG004","lowerLimit":"0.8","upperLimit":"90.6","value":"33.3"},{"groupId":"OG005","lowerLimit":"13.7","upperLimit":"78.8","value":"44.4"},{"comment":"NA indicates that upper and lower limits of CI were not estimable as there were no patients with CR or PR in that disease cohort.","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"description":"ORR was defined as the percentage of patients with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. BOR was defined as the best response recorded from the start of study treatment until documented RECIST v1.1 progression or the start date of new anticancer therapy, whichever came first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had a reduction in short axis to \\<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with microsatellite stable, locally advanced or metastatic CRC that was previously treated with at least 3 prior lines of therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.","id":"OG000","title":"Dose Expansion Phase: Cohort A: CRC"},{"description":"Patients with thoracic NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.","id":"OG001","title":"Dose Expansion Phase: Cohort B1: Thoracic NETs"},{"description":"Patients with GEP NET who had progressive, locally advanced or metastatic, low-to-intermediate grade (Grade 1 or Grade 2), well-differentiated NETs that progressed on at least 1 line of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.","id":"OG002","title":"Dose Expansion Phase: Cohort B2: GEP NETs"},{"description":"Patients with locally advanced or metastatic SCLC that was previously progressed on first-line chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.","id":"OG003","title":"Dose Expansion Phase: Cohort C: SCLC"},{"description":"Patients with microsatellite stable, PD-L1 ≥5%, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC) and were previously treated with at least 2 lines of standard therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.","id":"OG004","title":"Dose Expansion Phase: Cohort D: GC"},{"description":"Patients with UPS who progressed on, or had discontinued due to intolerable toxicity to, at least 1 line of standard therapy or were unsuitable for standard frontline cytotoxic chemotherapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.","id":"OG005","title":"Dose Expansion Phase: Cohort E2: UPS"},{"description":"Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.","id":"OG006","title":"Dose Expansion Phase: Cohort F: ATC"}],"paramType":"NUMBER","populationDescription":"The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab.","reportingStatus":"POSTED","timeFrame":"Tumor assessments performed every 6 weeks (+/-1 week) for the first 24 weeks and every 9 weeks (+/-1 week) thereafter, up to a maximum of approximately 37 months","title":"Dose Expansion Phase: Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of patients"}